within Pharmacolibrary.Drugs.ATC.N;

model N05CC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Chloralodol is a sedative-hypnotic drug, structurally related to chloral hydrate. It was formerly used for its sleep-inducing and calming effects, largely in the early to mid 20th century. The drug is no longer in common clinical use or approved for modern pharmaceutical applications due to its safety profile and the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic studies or published reports with quantitative pharmacokinetic parameters for chloralodol found in indexed biomedical literature. All parameters below are estimated based on typical values for related sedative-hypnotics such as chloral hydrate.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Robson, R (2015). Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. <i>Clinical drug investigation</i> 35(10) 625–632. DOI:<a href=&quot;https://doi.org/10.1007/s40261-015-0320-8&quot;>10.1007/s40261-015-0320-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26334726/&quot;>https://pubmed.ncbi.nlm.nih.gov/26334726</a></p></li><li><p>Freedman, MD, &amp; Somberg, JC (1991). Pharmacology and pharmacokinetics of amiodarone. <i>Journal of clinical pharmacology</i> 31(11) 1061–1069. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1991.tb03673.x&quot;>10.1002/j.1552-4604.1991.tb03673.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1753010/&quot;>https://pubmed.ncbi.nlm.nih.gov/1753010</a></p></li><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2021). Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. <i>Pharmaceutical research</i> 38(8) 1345–1356. DOI:<a href=&quot;https://doi.org/10.1007/s11095-021-03078-w&quot;>10.1007/s11095-021-03078-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34341958/&quot;>https://pubmed.ncbi.nlm.nih.gov/34341958</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CC02;
